Related Experiment Video
Updated: Aug 22, 2026
Bone Marrow Transplantation Procedures in Mice to Study Clonal Hematopoiesis
Published on: May 26, 2021
[Allogenic bone marrow transplantation in chronic myeloid leukemias]
Insights
Allogenic bone marrow (ABM) transplantation is effective for chronic myeloid leukemia (CML), especially in the chronic phase. This treatment offers a high chance of long-term molecular remission for CML patients.
Area of Science:
- Hematology
- Oncology
- Transplantation Immunology
Context:
- Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm.
- Allogenic bone marrow (ABM) transplantation is a potential curative therapy for CML.
- Disease phase significantly impacts transplantation outcomes.
Purpose:
- To evaluate the efficacy and role of allogenic bone marrow (ABM) transplantation in treating chronic myeloid leukemia (CML).
- To assess outcomes based on the phase of CML at the time of transplantation.
Summary:
- 44 ABM transplantations were performed in 37 chronic phase and 7 advanced phase CML patients.
- Complete molecular remission was achieved in 59% of patients (67.6% in chronic phase vs. 14.3% in advanced phase).
- Long-term remission maintenance was observed in 75% of chronic phase patients, with low recurrence rates (14%) and high efficacy of donor lymphocyte infusions.
Impact:
- ABM transplantation, particularly in the chronic phase, demonstrates high efficacy for CML treatment.
- The procedure can lead to long-term molecular remission in a significant proportion of patients.
- Outcomes highlight the critical importance of disease phase in predicting successful CML transplantation.
Aim:
To assess the role of allogenic bone marrow (ABM) transplantation in chronic myeloid leukemia (CML).
Material And Methods:
44 ABM transplantations were performed in 37 CML patients in the chronic phase and 7 patients in acceleration or blast crisis.
Results:
A complete molecular remission was achieved in 26 (59%) patients: 67.6% after ABM transplantation in the chronic phase and only 14.3% after myelotransplantation in non-chronic phase. Follow-up was 8-150 months (median--59 months). Early lethality after ABM transplantation in the chronic phase was under 14%. A phase of the disease plays a key role in ABM transplantation. If it is made in a chronic phase, CML recurrence rate is low (in our series it was 14%), efficacy of donor's bone marrow lymphocyte transfusions is high. The second complete molecular remission was achieved in 3 of 4 cases of posttransplantation recurrences. Probability of maintenance of a complete remission after ABM transplantation in a chronic phase was 75%, recurrence-free survival--64%, uneventful survival 55% for 90 months.
Conclusion:
The experience of many years demonstrates high efficacy of ABM transplantation in the treatment of chronic myeloid leukemia. It promotes long-term molecular remission the maintenance of which did not require therapy in 65% patients.
Related Concept Videos
01:22Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
01:21Stem Cell Therapy for Tissue Regeneration
Types of Stem Cells used in Stem Cell Therapy
The two main cell types that...